Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BVT.28949 dose-ranging trial in ocular hypertension and open angle glaucoma
2006-000168-10Phase 2Completed
- Sponsor
- Sobi
- Start
- Jun 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of BVT.28949 in ocular hypertension and open-angle glaucoma (OAG) (3 arms), sponsored by Sobi. Primary endpoint: Mean change in diurnal intraocular pressure at 4 weeks. Started Jun 2006; status: completed.
02
Drugs
BVT.28949
03
Conditions
ocular hypertensionopen-angle glaucoma (OAG)
Beyond the preview
Go deeper on 2006-000168-10.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-000168-10.